Aegle Therapeutics isolates extracellular vesicles (EVs) secreted by allogeneic bone marrow derived mesenchymal stem cells (BM-MSCs) to treat severe dermatological conditions including burns and epidermolysis bullosa (EB), a rare pediatric connective tissue disorder. Its proprietary extracellular vesicle isolation technology allows them to harness the healing power of mesenchymal stem cells without the risk of cell proliferation or engraftment, with higher production yields and at a lower cost.
Active
January 2020
Active
January 2020
Employees: 11-50
Total raised: $10.5M
Founded date: 2019
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 30.09.2020 | Series A | $6.5M | - |
| 08.01.2020 | - | $4M | - |
Mentions in press and media 13
| Date | Title | Description |
| 13.02.2024 | Meet February Pitch Presenter Aegle Therapeutics’ Shelley Hartman: Healing with EVs | Last year was a very good year for VisionTech. Applying strict criteria, we completed 18 deals worth $2.88 million. We’re continuing our thesis this year, looking hard at leadership, the unmet needs being met, milestones achieved, and deal ... |
| 21.07.2021 | Ocean Azul closes Fund 2 at over $40 million, with a South Florida commitment | Facebook Tweet Pin LinkedIn Email Ocean Azul Partners, a Miami-based early-stage venture firm, announced today that it has closed its second fund at over $40 million and has already invested in nine companies. With the new fund, both global... |
| 02.12.2020 | Aegle Therapeutics’ big mission: Tackling a horrific pediatric disorder | Facebook Tweet Pin LinkedIn Email Dr. Evangelos Badiavas, a dermatologist at the University of Miami Health System and cofounder of Aegle Therapeutics, a biotech company, has spent most of his career working with stem cells and how they can... |
| 18.11.2020 | Q&A with David Zinn of Ocean Azul: A global fund, yet so Miami | Facebook Tweet Pin LinkedIn Email Coral Gables-based venture firm Ocean Azul has invested in 19 startups in three years, five of them based in South Florida. The story of Ocean Azul Partners is as Miami as the venture capital firm’s name. M... |
| 30.09.2020 | Aegle Therapeutics Closes $6.5M Series A Financing | Aegle Therapeutics Corporation, an Arlington and Miami-based biotechnology company developing extracellular vesicles as therapy, completed a $6.5M Series A round of financing. Investors included Tellus BioVentures, New World Angels, DEFTA H... |
| 30.09.2020 | Aegle, a Miami biotech startup, raises $6.5 million Series A round | Facebook Tweet Pin LinkedIn Email Aegle Therapeutics, a Miami biotechnology startup, today announced that it has closed a $6.5 million Series A round of financing. Investors in this round included Tellus BioVentures, DEFTA Healthcare Techno... |
| 29.09.2020 | Aegle Therapeutics Completes $6.5M Series A | Aegle Therapeutics Corporation, a first-in-class biotechnology company developing extracellular vesicles as therapy, today announced the completion of a $6.5M Series A round of financing. Aegle's groundbreaking therapy is initially being de... |
| 08.01.2020 | Miami biotech startup Aegle Therapeutics draws $4M investment round | Facebook Tweet Pin LinkedIn Email CEO Shelley Hartman Aegle Therapeutics, a biotech startup that sprouted from IP licensed from the University of Miami, now will proceed to its first clinical trial, helped by a $4 million round led by Boca ... |
| 07.01.2020 | Aegle Therapeutics Announces $4M Financing | MIAMI, FL, Aegle Therapeutics today announced the closing of a $4M financing. >> Click here for more funding data on Aegle Therapeutics >> To export Aegle Therapeutics funding data to PDF and Excel, click here Aegle Thera... |
| 07.01.2020 | Aegle Therapeutics Announces $4M Financing | Aegle Therapeutics Corp., a first in class biotechnology company isolating extracellular vesicles, including exosomes, secreted by mesenchymal stem cells as therapy, today announced the closing of a $4M financing. Aegle's platform technolog... |
Show more